Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Jingyu Min

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6739-2892; OpenAlex author ID A5010105557, A5039419101. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. The prognostic role of lymphocyte-to-monocyte ratio in patients with resectable pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.7717/peerj.17585↗
  2. The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. Co-author DOI 10.1002/1878-0261.12836↗
  3. Methyl-CpG-binding domain 3 inhibits stemness of pancreatic cancer cells via Hippo signaling. Co-author DOI 10.1016/j.yexcr.2020.112091↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Aihua Gong · 2 shared papers, 2020–2021 · strength 0.22
  2. Min Xu · 2 shared papers, 2020–2021 · strength 0.22
  3. Haipeng Li · 1 shared paper, 2024 · strength 0.22
  4. Youli Zhang · 1 shared paper, 2021 · strength 0.12
  5. Yawen Liu · 1 shared paper, 2021 · strength 0.12
  6. Huizhi Wang · 1 shared paper, 2021 · strength 0.12
  7. Wei Chen · 1 shared paper, 2020 · strength 0.10
  8. Huizhi Wang · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.